APO RESEARCH · REPORT
Meningococcal Vaccine
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
Product & engineering
Understand the product.
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
Selected research
Market Structure
Global Meningococcal Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%.
Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent.
Read the full market overview
In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.
This report provides an overview of the global Meningococcal Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Meningococcal Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Meningococcal Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Meningococcal Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.
Meningococcal Vaccine Segment by Company
Novartis
GSK
Merck
CSL
Baxter
JN International Medical Corporation
Serum Institute of India
Bio-Med
China National Biotec Group
Hualan Bio
Walvax
Zhifei
Meningococcal Vaccine Segment by Type
Meningtits A
Polysaccharide Meningtitis AC
Meningitis ACYW
Meningococcal Vaccine Segment by Application
6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
Meningococcal Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Meningococcal Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Meningococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Meningococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Meningtits A
- Polysaccharide Meningtitis AC
- Meningitis ACYW
Applications
- 6 Months-15Year
- over 3 Year
- over 2 Year
- over 3 Months
Companies covered
- Novartis
- GSK
- Merck
- CSL
- Baxter
- JN International Medical Corporation
- Serum Institute of India
- Bio-Med
- China National Biotec Group
- Hualan Bio
- Walvax
- Zhifei
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Meningococcal Vaccine Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Meningococcal Vaccine Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Meningococcal Vaccine Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Meningococcal Vaccine Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Meningococcal Vaccine Market Dynamics
- 2.1 Meningococcal Vaccine Industry Trends
- 2.2 Meningococcal Vaccine Industry Drivers
- 2.3 Meningococcal Vaccine Industry Opportunities and Challenges
- 2.4 Meningococcal Vaccine Industry Restraints
3 Meningococcal Vaccine Market by Manufacturers
- 3.1 Global Meningococcal Vaccine Revenue by Manufacturers (2021-2026)
- 3.2 Global Meningococcal Vaccine Sales by Manufacturers (2021-2026)
- 3.3 Global Meningococcal Vaccine Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Meningococcal Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Meningococcal Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Meningococcal Vaccine Manufacturers, Product Type & Application
- 3.7 Global Meningococcal Vaccine Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Meningococcal Vaccine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Meningococcal Vaccine Players Market Share by Revenue in 2025
- 3.8.3 2025 Meningococcal Vaccine Tier 1, Tier 2, and Tier 3
4 Meningococcal Vaccine Market by Type
- 4.1 Meningococcal Vaccine Type Introduction
- 4.1.1 Meningtits A
- 4.1.2 Polysaccharide Meningtitis AC
- 4.1.3 Meningitis ACYW
- 4.2 Global Meningococcal Vaccine Sales by Type
- 4.2.1 Global Meningococcal Vaccine Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Meningococcal Vaccine Sales by Type (2021-2032)
- 4.2.3 Global Meningococcal Vaccine Sales Market Share by Type (2021-2032)
- 4.3 Global Meningococcal Vaccine Revenue by Type
- 4.3.1 Global Meningococcal Vaccine Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Meningococcal Vaccine Revenue by Type (2021-2032)
- 4.3.3 Global Meningococcal Vaccine Revenue Market Share by Type (2021-2032)
5 Meningococcal Vaccine Market by Application
- 5.1 Meningococcal Vaccine Application Introduction
- 5.1.1 6 Months-15Year
- 5.1.2 over 3 Year
- 5.1.3 over 2 Year
- 5.1.4 over 3 Months
- 5.2 Global Meningococcal Vaccine Sales by Application
- 5.2.1 Global Meningococcal Vaccine Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Meningococcal Vaccine Sales by Application (2021-2032)
- 5.2.3 Global Meningococcal Vaccine Sales Market Share by Application (2021-2032)
- 5.3 Global Meningococcal Vaccine Revenue by Application
- 5.3.1 Global Meningococcal Vaccine Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Meningococcal Vaccine Revenue by Application (2021-2032)
- 5.3.3 Global Meningococcal Vaccine Revenue Market Share by Application (2021-2032)
6 Global Meningococcal Vaccine Sales by Region
- 6.1 Global Meningococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Meningococcal Vaccine Sales by Region (2021-2032)
- 6.2.1 Global Meningococcal Vaccine Sales by Region (2021-2026)
- 6.2.2 Global Meningococcal Vaccine Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Meningococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Meningococcal Vaccine Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Meningococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Meningococcal Vaccine Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Meningococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Meningococcal Vaccine Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Meningococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Meningococcal Vaccine Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Meningococcal Vaccine Revenue by Region
- 7.1 Global Meningococcal Vaccine Revenue by Region
- 7.1.1 Global Meningococcal Vaccine Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Meningococcal Vaccine Revenue by Region (2021-2026)
- 7.1.3 Global Meningococcal Vaccine Revenue by Region (2027-2032)
- 7.1.4 Global Meningococcal Vaccine Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Meningococcal Vaccine Revenue (2021-2032)
- 7.2.2 North America Meningococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Meningococcal Vaccine Revenue (2021-2032)
- 7.3.2 Europe Meningococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Meningococcal Vaccine Revenue (2021-2032)
- 7.4.2 Asia-Pacific Meningococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Meningococcal Vaccine Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Meningococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Novartis
- 8.1.1 Novartis Company Information
- 8.1.2 Novartis Business Overview
- 8.1.3 Novartis Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Novartis Meningococcal Vaccine Product Portfolio
- 8.1.5 Novartis Recent Developments
- 8.2 GSK
- 8.2.1 GSK Company Information
- 8.2.2 GSK Business Overview
- 8.2.3 GSK Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 GSK Meningococcal Vaccine Product Portfolio
- 8.2.5 GSK Recent Developments
- 8.3 Merck
- 8.3.1 Merck Company Information
- 8.3.2 Merck Business Overview
- 8.3.3 Merck Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Merck Meningococcal Vaccine Product Portfolio
- 8.3.5 Merck Recent Developments
- 8.4 CSL
- 8.4.1 CSL Company Information
- 8.4.2 CSL Business Overview
- 8.4.3 CSL Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 CSL Meningococcal Vaccine Product Portfolio
- 8.4.5 CSL Recent Developments
- 8.5 Baxter
- 8.5.1 Baxter Company Information
- 8.5.2 Baxter Business Overview
- 8.5.3 Baxter Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Baxter Meningococcal Vaccine Product Portfolio
- 8.5.5 Baxter Recent Developments
- 8.6 JN International Medical Corporation
- 8.6.1 JN International Medical Corporation Company Information
- 8.6.2 JN International Medical Corporation Business Overview
- 8.6.3 JN International Medical Corporation Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 JN International Medical Corporation Meningococcal Vaccine Product Portfolio
- 8.6.5 JN International Medical Corporation Recent Developments
- 8.7 Serum Institute of India
- 8.7.1 Serum Institute of India Company Information
- 8.7.2 Serum Institute of India Business Overview
- 8.7.3 Serum Institute of India Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Serum Institute of India Meningococcal Vaccine Product Portfolio
- 8.7.5 Serum Institute of India Recent Developments
- 8.8 Bio-Med
- 8.8.1 Bio-Med Company Information
- 8.8.2 Bio-Med Business Overview
- 8.8.3 Bio-Med Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Bio-Med Meningococcal Vaccine Product Portfolio
- 8.8.5 Bio-Med Recent Developments
- 8.9 China National Biotec Group
- 8.9.1 China National Biotec Group Company Information
- 8.9.2 China National Biotec Group Business Overview
- 8.9.3 China National Biotec Group Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 China National Biotec Group Meningococcal Vaccine Product Portfolio
- 8.9.5 China National Biotec Group Recent Developments
- 8.10 Hualan Bio
- 8.10.1 Hualan Bio Company Information
- 8.10.2 Hualan Bio Business Overview
- 8.10.3 Hualan Bio Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Hualan Bio Meningococcal Vaccine Product Portfolio
- 8.10.5 Hualan Bio Recent Developments
- 8.11 Walvax
- 8.11.1 Walvax Company Information
- 8.11.2 Walvax Business Overview
- 8.11.3 Walvax Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Walvax Meningococcal Vaccine Product Portfolio
- 8.11.5 Walvax Recent Developments
- 8.12 Zhifei
- 8.12.1 Zhifei Company Information
- 8.12.2 Zhifei Business Overview
- 8.12.3 Zhifei Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Zhifei Meningococcal Vaccine Product Portfolio
- 8.12.5 Zhifei Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Meningococcal Vaccine Value Chain Analysis
- 9.1.1 Meningococcal Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Meningococcal Vaccine Production Mode & Process
- 9.2 Meningococcal Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Meningococcal Vaccine Distributors
- 9.2.3 Meningococcal Vaccine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst